Completed PHASE4 INTERVENTIONAL 1-arm NCT03316482

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

Sponsor: Jin Soon Hwang

Conditions Central Precocious Puberty

Interventions Leuplin DPS 11.25mg

Updated 8 times since 2017 Last updated: Jun 1, 2020 Started: Jun 11, 2015 Primary completion: Aug 29, 2019 Completion: Dec 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Central Precocious Puberty and is currently completed. Jin Soon Hwang leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jul 2020 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Nov 2019 — Jul 2020 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE4
Nov 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jin Soon Hwang

Data source: Ajou University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suwon, South Korea